Ultragenyx Pharmaceutical PE Ratio 2012-2021 | RARE

Current and historical p/e ratio for Ultragenyx Pharmaceutical (RARE) from 2012 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Ultragenyx Pharmaceutical PE ratio as of October 22, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Ultragenyx Pharmaceutical PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-22 78.22 0.00
2021-06-30 95.35 $-5.34 0.00
2021-03-31 113.86 $-3.12 0.00
2020-12-31 138.43 $-3.14 0.00
2020-09-30 82.19 $-4.39 0.00
2020-06-30 78.22 $-5.22 0.00
2020-03-31 44.43 $-7.35 0.00
2019-12-31 42.71 $-7.12 0.00
2019-09-30 42.78 $-7.23 0.00
2019-06-30 63.50 $-7.01 0.00
2019-03-31 69.36 $-6.35 0.00
2018-12-31 43.48 $-3.91 0.00
2018-09-30 76.34 $-4.07 0.00
2018-06-30 76.87 $-4.20 0.00
2018-03-31 50.99 $-4.86 0.00
2017-12-31 46.38 $-7.11 0.00
2017-09-30 53.26 $-6.97 0.00
2017-06-30 62.11 $-6.74 0.00
2017-03-31 67.78 $-6.48 0.00
2016-12-31 70.31 $-6.20 0.00
2016-09-30 70.94 $-5.87 0.00
2016-06-30 48.91 $-5.26 0.00
2016-03-31 63.31 $-4.63 0.00
2015-12-31 112.18 $-3.91 0.00
2015-09-30 96.31 $-3.01 0.00
2015-06-30 102.39 $-2.48 0.00
2015-03-31 62.09 $-2.10 0.00
2014-12-31 43.88 $-2.32 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.306B $0.271B
Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company's product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76